Genprex Receives U.S. FDA Fast Track Designation for REQORSA™ in Combination With Keytruda® for the Treatment of Non-Small Cell Lung Cancer (NSCLC)
Genprex, Inc., today announced that the U.S. Food and Drug Administration (FDA) had granted Fast Track Designation (FTD) for the Company’s lead drug candidate, REQORSA™ Immunogene Therapy, in combinat ...